Summit Therapeutics (SMMT) Net Income towards Common Stockholders (2019 - 2024)

Summit Therapeutics has reported Net Income towards Common Stockholders for 6 years, with the latest figure at -$65.6 million in Q4 2024.

• For the quarter ending Q4 2024, Net Income towards Common Stockholders fell 81.23% year-over-year to -$65.6 million; the trailing twelve-month figure through Sep 2025 stood at -$65.6 million (up 68.03% YoY), and the FY2024 full-year result was -$234.7 million, up 61.84% from the prior year.
• Net Income towards Common Stockholders for Q4 2024 stood at -$65.6 million, down from -$60.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$6.1 million in Q1 2020, with the low at -$537.2 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$52.9 million across 5 years, with a median of -$20.4 million in 2022.
• Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 2324.2% — and 2024, when it surged 91.53%.
• Summit Therapeutics' Net Income towards Common Stockholders stood at -$13.5 million in 2020, then slumped by 100.13% to -$27.1 million in 2021, then climbed by 25.09% to -$20.3 million in 2022, then plunged by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
• The last three Net Income towards Common Stockholders figures came in at -$65.6 million (Q4 2024), -$60.8 million (Q3 2024), and -$62.7 million (Q2 2024), per Business Quant data.